SLC7A9 Gene (Cystinuria) Genetic Test – 2,800 AED

Executive Summary & Core Metrics

High-confidence molecular diagnosis of cystinuria predisposition via next-generation sequencing of the SLC7A9 gene, compliant with Dubai Healthcare City diagnostic standards.

✓ Accuracy Guarantee: 99.9% diagnostic sensitivity achieved through ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139) with orthogonal variant confirmation.
✓ Premium Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all UAE emirates.
✓ Clinical Guidance: Complimentary telephonic post-test consultation with a consultant medical geneticist for result interpretation and family counseling.
✓ Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The SLC7A9 gene test employs next-generation sequencing to detect pathogenic single-nucleotide variants and small insertions or deletions linked to cystinuria. Full coverage of all coding exons, splice-site junctions, and deep intronic regions enables early detection of hereditary kidney stone risk, allowing timely dietary and medical intervention to prevent recurrent urolithiasis.

Feature	Our SLC7A9 NGS Test	Standard Single-Gene Test
Methodology	Next-Generation Sequencing with copy number variation analysis	Sanger sequencing with limited variant detection
Gene Coverage	Full coding regions, splice sites, and deep intronic regions	Selected exons only
Turnaround Time	3 to 4 Weeks	4 to 6 Weeks
Sample Types	Whole Blood, Extracted DNA, One-Drop Blood on FTA Card	Whole Blood only
Price	2,800 AED	Competitive

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics, I underscore that this NGS-based test offers a powerful window into hereditary cystinuria risk. A pathogenic or likely pathogenic variant in SLC7A9 significantly elevates the probability of recurrent cystine stone formation, yet penetrance can vary. Clinical correlation with metabolic profiling, renal imaging, and family history remains indispensable. All results should be reviewed with a nephrologist and a certified genetic counsellor before any therapeutic or dietary adjustments are made.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Medication & Clinical Decision Guidance

⚠️ Do not discontinue prescribed medication without consulting your doctor. Genetic test results alone should never override a current treatment plan; always seek specialist advice before altering therapy.

Exclusion Criteria & Emergency Red Flags

Patients under 18 years without legal guardian consent as required by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Recent blood transfusion (less than 2 weeks) or haematopoietic stem cell transplant – may confound germline DNA analysis; physician clearance mandatory.
Known interfering substances such as EDTA contamination – a sample validity check is performed before processing.

🚨 ER Red Flags

If you experience severe flank pain, visible haematuria, fever, or signs of systemic infection, seek emergency medical attention immediately. These symptoms may indicate obstructive urolithiasis requiring urgent urological intervention.

Patient FAQ & Clinical Guidance

1. What is the SLC7A9 gene test and how is it performed?

The SLC7A9 gene test is a next-generation sequencing analysis that identifies pathogenic variants in the SLC7A9 gene associated with cystinuria. A whole blood sample, extracted DNA, or one-drop blood on an FTA card is collected. The assay covers all coding exons, splice junctions, and deep intronic regions with concurrent copy number variation detection, providing comprehensive germline evaluation.

2. How accurate is the test and what do the results mean?

Our NGS platform achieves over 99.9% analytical sensitivity for single-nucleotide variants and small insertions or deletions within SLC7A9. Results are classified according to ACMG/AMP guidelines: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, or benign. This classification informs clinical management, including dietary modification, potassium citrate therapy, or surgical planning.

3. Is home collection available across the UAE and when will I receive results?

Yes, VIP mobile phlebotomy with temperature-controlled cold-chain logistics is available daily from 8 AM to 11 PM in Dubai, Abu Dhabi, and all emirates. NGS results are delivered within 3 to 4 weeks of sample receipt. Appointment scheduling and insurance verification are handled via WhatsApp at +971 54 548 8731.

UAE Regulatory & Data Privacy Adherence

All genetic testing and patient data handling at DNA Labs UAE comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genetic information is encrypted, access-restricted, and processed under strict confidentiality protocols. No data is shared with third parties without explicit informed consent as mandated by UAE health data governance frameworks.

Clinical & Logistical Metadata

Test Name	SLC7A9 Gene (Cystinuria) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Whole Blood, Extracted DNA, One-Drop Blood on FTA Card
Methodology Used	Next-Generation Sequencing with Copy Number Variation Analysis
ICD-10-CM Code	E72.0
LOINC Code	94244-6
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE